Our science
Exploring the New Frontier
We have discovered and are developing a new class of drugs that we refer to as Membrane Acting IMmunomodulatorS or MAIMS. MAIMS exert their therapeutic effects by changing the fluidity of cellular plasma membranes.
tHE hISTORY OF maims
New Wine in Old Bottles
Humankind has uncomprehendingly been using MAIMS for millennia. Olive oil for instance has been in human use at least since the end of the Stone Age. Ethanol, produced by the fermentation of various carbohydrates such as grapes to make wine and corn to make whiskey is also a MAIM.
MAIMS in Recent Times
In the 19th century Modern Medicine was aborning. General anesthesia, antisepsis, X-rays for medical imaging, aspirin and the use of quinine for the treatment of malaria were all discovered and developed.
Our DISCOVERIES
SOME USES FOR MAIMS
In over 16 years of intensive research we have identified a multitude of medical uses for MAIMS. Among them are:
- The treatment of insulin resistance and diabetes
- The treatment of dyslipidemia
- The treatment of the neglected tropical disease Buruli Ulcer
- The treatment of Brown Recluse spider bite
- The treatment of musculoskeletal pain
- The treatment of overweight and obesity
- The treatment of inflammatory dermatoses such as seborrhea and acne
Our BUSINESS
Our Product is Intellectual Property
Indication Patent No. License Status
Insulin resistance US 10,251,857 B2 Available
Type 2 Diabetes US 11,026,912 B2 Available
Dyslipidemia US App. No. 62/978,785 Available
Brown Recluse Bite / PLD US 11,918,555 Available
Musculoskeletal Pain US 11,911,358 Available
Next Generation Insulin Resistance US App No. 18/806,476 Available
Next Generation Pain Reliever US App No. 18/806,476 Available
Our Product is Intellectual Property
Indication Patent No. License Status
Insulin resistance US 10,251,857 B2 Available
Type 2 Diabetes US 11,026,912 B2 Available
Dyslipidemia US App. No. 62/978,785 Available
Brown Recluse Bite / PLD US 11,918,555 Available
Musculoskeletal Pain US 11,911,358 Available
Next Generation Insulin Resistance US App No. 18/806,476 Available
Next Generation Pain Reliever US App No. 18/806,476 Available
We have become aware that a third party is claiming that they hold a license to New Frontier Labs intellectual property, this is not true. All third party rights to NFL IP were terminated on March 7, 2024 for breach of contract.
Our Goal
We are researchers. We seek to out-license the fruits of our studies for further development and commercialization. All of the above indications have been proven in human studies. Contact us for more details. .
SCIENTIFIC pUBLICATIONS And Patents
Peer Reviewed Publications
Izbicka E, Streeper RT. Mixtures of Diethyl Azelate as Novel Nonopioid Modalities for Pain Management. Cureus. 2025 Mar 3;17(3):e79960. doi: 10.7759/cureus.79960. PMID: 40177435; PMCID: PMC11964120.
Streeper RT, Louden C, Izbicka E Oral Azelaic Acid Ester Decreases Markers of Insulin Resistance in Overweight Human Male Subjects. in vivo 34:1173-1186 (2020)
https://doi.org/10.21873/invivo.11890
Izbicka E, Streeper RT, Louden C Adaptive Membrane Fluidity Modulation: A Feedback Regulated Homeostatic System and Target for Pharmacological Intervention. in vivo 35: 3073-3095 (2021)
https://doi.org/10.21873/invivo.12603
Izbicka E, Streeper RT Adaptive Membrane Fluidity Modulation: A Feedback Regulated Homeostatic System Hiding in Plain Sight. in vivo 35: 2991-3000 (2021)
https://doi.org/10.21873/invivo.12594
Izbicka E, Streeper RT Azelaic Acid Esters as Pluripotent Immunomodulatory
Molecules: Nutritional Supplements or Drugs. Nutraceuticals 2021, 1:42-53 (2021)
https://doi.org/10.3390/nutraceuticals1010006
Streeper RT, Izbicka E Diethyl Azelate for the Treatment of Brown Recluse
Spider Bite, a Neglected Orphan Indication. in vivo 36:86-93 (2022)
https://doi.org/10.21873/invivo.12679
Izbicka E, Streeper RT, Louden C Membrane Active Immunomodulator As a Novel Therapy for an Infectious Bacterial Disease, Buruli Ulcer. In Vivo 36: 2615-2629 (2022) https://doi.org/10.21873/invivo.12996
Izbicka E, Streeper RT 2023 Mitigation of Insulin Resistance by Natural Products from a New Class of Molecules, Membrane-Active Immunomodulators. Pharmaceuticals 16:913 (2023)
https://doi.org/10.3390/ph16070913
Izbicka E, Streeper RT (2023) Cancer drug development yesterday, today and tomorrow https://medicalxpress.com/news/2023-08-editorial-cancer- drug-yesterday-today.html https://doi.org/10.18632/oncoscience.583ist.
Diethyl Azelate for the Treatment of Brown Recluse
Spider Bite, a Neglected Orphan Indication: A Commentary
J Dermatol & Skin Sci. 2024;6(2):4-8
Granted United States Patents
AZELAIC ACID ESTERS IN THE TREATMENT OF INSULIN RESISTANCE US 10,251,857 B2 (April 9, 2019)
AZELAIC ACID ESTERS IN THE TREATMENT OF INSULIN RESISTANCE US 11,026,912 B2 (June 8, 2021)
DICARBOXYLIC ACID ESTERS FOR INDUCING AN ANALGESIC EFFECT US 11,911,358 (February 27, 2024)
DICARBOXYLIC ACID ESTERS FOR THE TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH PHOSPHOLIPASE D TOXIN US 11,918,555 (March 5, 2024)
Pending United States Patents
AZELAIC ACID ESTERS IN THE TREATMENT OR PREVENTION OF DYSLIPIDEMIA AND ASSOCIATED CONDITIONS https://patents.justia.com/patent/20210251939
COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF DICARBOXYLIC ACID ESTERS, AND USES THEREOF U.S. Patent Application No. 18/806,476
Granted International Patents
Patents based on US 10,251,857 (Expiry 2037)